Skip to main content

Table 1 DAAs after renal transplantation

From: Successful treatment of chronic hepatitis C virus genotype 1b infection of a patient with compensated cirrhosis after renal transplantation using daclatasvir-asunaprevir combination therapy: a case report and literature review

Number of case Sex
Male/female
Platelets count, ×103/mm3, median (range) CNI HCV genotype DAA regimen Rate of SVR12 Reference
35 15:10 160 (180–290) Tac:9
CyA:1
1a: 4
1b:15
2: 2
3:1
4:3
SOF/LDV:9
SOF/SMV:6
SOF/DCV:4
SOF/RBV:3
SOF:LDV/RBV:1
SOF/SMV/RBV:1
PEG-IFN/RBV/SOF:1
35/35 [13]
20 16:4 180 (59–284) Tac:19
CyA:1
1:4
1a:6
1a/1b:1
1b:6
2b:2
2a/2c:1
SOF/LDV:7
SOF/SMV:9
SOF/DCV:1
SOF/RBV:3
20/20 [14]
4 2:1 201 (158–269) Tac:3 4:3 SOF/RBV:3 3/3 [15]
  1. CNI calcineurin inhibitor, CyA cyclosporin A, DAA direct-acting antivirals, DCV daclatasvir, HCV hepatitis C virus, LDV ledipasvir, PEG-IFN pegylated interferon, RBV ribavirin, SMV simeprevir, SOF sofosbuvir, SVR12 sustained a virologic response at 24 weeks, Tac tacrolimus